Key financial ranges
Market cap · USD equivalent
P/E ratio
Annual revenue · USD equivalent
Revenue growth
Valuation & profitability
Price / sales
Annual net income · USD equivalent
Net profit margin
Cash & debt
Cash · USD equivalent
Total debt · USD equivalent
Net cash · USD equivalent
Debt / revenue
| Company | Market cap | P/E | Revenue | Rev. growth | Net income | Cash | Debt | AI value |
|---|---|---|---|---|---|---|---|---|
| MKTXMarketaxess Holdings Inc | $5.75B | 19.3× | $846.27M | +3.6% | $246.63M | $245.79M | $178.91M | Fair valued |
| BGCBGC Group, Inc. | $5.75B | 30.3× | $2.44B | +34.7% | $154.96M | $766.85M | $2B | Undervalued |
| LGNLegence Corp. | $5.75B | — | $2.55B | +21.5% | -$59.78M | $291.98M | $1.2B | Fair valued |
| NTSKNetskope Inc | $5.73B | — | $709M | +31.7% | -$679.39M | $220.85M | $34.12M | Overvalued |
| VSECVse Corp | $5.73B | 75.2× | $1.11B | +41.5% | $11.7M | $75.36M | $1.03B | Overvalued |
| HLNEHamilton Lane INC | $5.72B | 15.8× | $758.99M | +6.5% | $249.18M | $349.73M | $364.79M | Undervalued |
| LGNDLigand Pharmaceuticals Inc | $5.71B | 30.6× | $268.09M | +60.4% | $124.45M | $1.01B | $1.13B | Fair valued |
| AROCArchrock, Inc. | $5.69B | 17.4× | $1.49B | +28.7% | $322.29M | $2M | $2.36B | Fair valued |
| BYDBoyd Gaming Corp | $5.68B | 3.4× | $4.09B | +4.1% | $1.84B | $322.71M | $3.26B | Undervalued |
| CRUSCirrus Logic, Inc. | $5.68B | 13.9× | $2B | +5.3% | $414.41M | $810.67M | $130.46M | Undervalued |
| FTDRFrontdoor, Inc. | $5.67B | 21.8× | $2.09B | +13.6% | $255M | $627M | $1.15B | Fair valued |
| BBUCBrookfield Business Corp | $5.66B | — | $27.46B | -32.4% | $387M | $3.55B | $44.57B | Undervalued |
| OBDCBlue Owl Capital Corp | $5.65B | 20.1× | $1.85B | +15.9% | $627.41M | $238.05M | $7.9B | Undervalued |
| CVLTCommvault Systems Inc | $5.65B | 87.0× | $1.18B | +18.9% | $70.66M | $929.84M | $35.73M | Fair valued |
| ERASErasca, Inc. | $5.65B | — | — | — | — | $42.54M | $44.71M | Overvalued |
| CMBTCmb.tech NV | $5.64B | 6.8× | $940.25M | -23.9% | $870.83M | $155.05M | $5.76B | Fair valued |
| RITMRithm Capital Corp. | $5.64B | 16.8× | $4.59B | -6.7% | $697.06M | $1.66B | $30.11B | Undervalued |
| NOVTNovanta Inc | $5.63B | 95.1× | $980.6M | +3.3% | $53.83M | $718.65M | $285.6M | Overvalued |
| AMRXAmneal Pharmaceuticals, Inc. | $5.62B | 36.7× | $3.02B | +8.0% | $72.06M | $127.64M | $2.57B | Fair valued |
| MXLMaxlinear, Inc | $5.62B | — | $467.64M | +29.7% | -$136.68M | $64.81M | $148.2M | Fair valued |